FDA Extends Dupilumab COPD Decision to September 2024
The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.
Source: hcplive.com
Stay updated with breaking news from Lung Imaging Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.